Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The Roivant company unveiled the hire alongside other executive appointments and news of the in-licensing of a drug to treat excessive sweating.
AstraZeneca gains a source of bispecific and multispecific antibodies in return for $10 million upfront and up to $200 million in milestones.
Reckitt Benkiser spinout Indivior agreed to a $294 million deal with C4X Discovery for a drug candidate to treat addiction.
Arpeggio’s technology combines new RNA sequencing technologies with machine learning to better understand drug candidates’ mechanism of action.
Bluebird exercised an option to co-promote and co-develop its bb2121 treatment in the U.S.
The revisions see Abide regain control of a phase 2-ready CNS drug and pocket an upfront fee in exchange for an earlier-stage drug.
Homology pulled off a $144 million offering of 9 million shares at $16 each, at the high end of the range.
Roivant Sciences is adding a late-phase drug to its pipeline: Nabriva's pneumonia antibiotic lefamulin.
AbbVie is abandoning plans to seek out an FDA quick OK for its troubled oncology drug Rova-T in third-line relapsed/refractory small cell lung cancer.
Prothena is getting $150 million up front for work on a trio of proteins implicated in neuro diseases.